Treating chronic neurodisorders

Depressive Disorders: A Worrying Landscape

A huge public health issue and a huge, growing market

Depressive disorder

Urgent Needs for a better understanding of the disease and for innovation

20% to 40% patients are partial or non responders;
there is a 3-4 week delay before treatments start bringing benefits;
there are systematic, serious side effects (“serotonin syndrom”, mania/hypomania, bleeding, nausea, …);
50% patients discontinue treatment within 6 months because of side effects;
10% patients commit suicide!

they regulate monoamines neurotransmission (SSRIs, SNRIs).

We believe MAPREG is on the verge to bring a cutting-edge new drug to patients, a drug that is safer than any other drug, and a drug that is based on a completely new mechanism of action, able to tackle Treatment-Resistant cases.

The DEPSTER project, designed and piloted by MAPREG, made the awaited first original proof of concept to relieve depressive situation in relevant animal models.
Now Phase 2 clinical trial is about to be launched.

MAP4343 fills the gaps

A competitive innovative program granted 6th by EUROSTARS

In 3 different animal models of depressive disorder, MP4343*:

*MAP4343 was systematically compared to PROZAC, and proves better in all outcomes.

Aging Brain

Brain inherently ages and becomes slower, subject to failure of memory with correlative loss of self-confidence and desire to act. MAP4343 pharmacological profile allows to propose it as a safe drug to help people fight their cognitive impairments as well as mood disorders.

CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.